The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma

BACKGROUND: Malignant Pleural Mesothelioma (MPM) is an aggressive tumor arising from mesothelial cells lining the pleural cavities characterized by resistance to standard therapies. Most of the molecular steps responsible for pleural transformation remain unclear; however, several growth factor sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignochino, Ymera, Dell’Aglio, Carmine, Inghilleri, Simona, Zorzetto, Michele, Basiricò, Marco, Capozzi, Federica, Canta, Marta, Piloni, Davide, Cemmi, Francesca, Sangiolo, Dario, Gammaitoni, Loretta, Soster, Marco, Marchiò, Serena, Pozzi, Ernesto, Morbini, Patrizia, Luisetti, Maurizio, Aglietta, Massimo, Grignani, Giovanni, Stella, Giulia M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429519/
https://www.ncbi.nlm.nih.gov/pubmed/25952930
http://dx.doi.org/10.1186/s12885-015-1363-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4429519/
https://www.ncbi.nlm.nih.gov/pubmed/25952930
http://dx.doi.org/10.1186/s12885-015-1363-1

Ejemplares similares